Timosin alpha-1 immunomodulating properties by M. V. Mayevskaya

“…Efficacy of Timosin alpha-1 was demonstrated in the treatment of one of the most difficult groups of patients with persistent hepatitis C virus infection – non-responders at combined treatment by interferon and ribavirin. …”
Get full text

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy by M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin

“…Daclatasvir is NS5A inhibitor which has proven high antiviral activity in relation to all hepatitis C virus genotypes. Prescription of the drug in combination to pegilated interferon and ribavirin for treatment-naive patients made possible to reduce treatment duration from 48 to 24 weeks and to increase frequency of sustained virologic response (SVR) to 87% in 1b genotypeand to 100% — in 4-th genotype. …”
Get full text

Agent based modelling of blood borne viruses: a scoping review by Seun Ale, Elizabeth Hunter, John D. Kelleher

“…However, these models do not capture the impact of individual and social factors that affect the spread of common blood-borne viruses (BBVs) such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). Agent-based modelling (ABM) is an alternative modelling approach that is gaining popularity in public health and epidemiology. …”
Get full text

Seroprevalence of TORCH Viral Agents in Pregnant Women in Turkey: Systematic Review and Meta-Analysis by Elmas Pinar Kahraman Kilbas, Ihsan Hakki Ciftci, Imdat Kilbas, Hande Toptan

“…Rubella Virus, Cytomegalovirus (CMV), Herpes Simplex Virus-2 (HSV-2), Hepatitis B (HBV) and Hepatitis C virus (HCV) can cause serious fetal disease. …”
Get full text

Transmission of HIV and HCV within Former Soviet Union Countries by Lazzat Aibekova, Aizada Bexeitova, Arailym Aldabergenova, Gonzalo Hortelano, Zhangwen Ge, Feng Yi, Yiming Shao, Jack DeHovitz, Sten H. Vermund, Syed Ali

“…To examine the transmission of blood-borne infections within this region, we analyzed the phylogenetic relationship of publically available sequences of two blood-borne viruses, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), from FSU countries. …”
Get full text

Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based A... by Teresa Urraro, Laura Gragnani, Alessia Piluso, Alessio Fabbrizzi, Monica Monti, Elisa Fognani, Barbara Boldrini, Jessica Ranieri, Anna Linda Zignego

“…Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV) infection, manifesting as a systemic vasculitis. …”
Get full text

Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance by M. Ghabril, R. C. Dickson, M. Krishna, R. Lloyd, J. Aranda-Michel, A. Keaveny, R. Satyanarayana, H. Bonatti

“…Background. Hepatitis C virus (HCV) nondetectability in the liver may predict a sustained viral response (SVR) in patients with an end of treatment response. …”
Get full text

Global Occupational Exposure to Blood and Body Fluids among Healthcare Workers: Systematic Review and Meta-Analysis by Dechasa Adare Mengistu, Gebisa Dirirsa, Elsai Mati, Dinku Mekbib Ayele, Kefelegn Bayu, Wegene Deriba, Fekade Ketema Alemu, Yohannes Mulugeta Demmu, Yohanis Alemeshet Asefa, Abraham Geremew

“…Occupational exposure to blood and body fluids has become a serious public health problem for healthcare workers and is a major risk for the transmission of various infections such as human immune-deficiency virus, hepatitis B virus, and hepatitis C virus. This systematic review and meta-analysis aims to determine the career time and previous one-year global pooled prevalence of occupational exposure to blood and body fluids among healthcare workers. …”
Get full text

Liver HLA-E Expression Is Associated with Severity of Liver Disease in Chronic Hepatitis C by Roberta C. Araújo, Fabricio C. Dias, Bruna C. Bertol, Deisy M. Silva, Patrícia H. Almeida, Andreza C. Teixeira, Fernanda F. Souza, Marcia G. Villanova, Leandra N. Z. Ramalho, Eduardo A. Donadi, Ana L. C. Martinelli

“…Hepatitis C virus (HCV) can escape from innate and adaptive immunity, making the immune response ineffective. …”
Get full text

Cardiovascular disease and its risk factors among people living with HIV: A systematic review and meta-analysis by Min Du, Shimo Zhang, Min Liu, Jue Liu

“…Among the 14 risk factors analyzed, the most prevalent was a history of CVD (odds ratio [OR]=3.47), followed by age (per 10-year increase) (OR=1.79), current smoking (OR=1.76), hypertension (OR=1.57), smoking (OR=1.53), diabetes (OR=1.50), previous smoking (OR=1.30), and hepatitis C virus (HCV) infection (OR=1.18). However, there was no statistical significance associated with HIV-specific factors (abacavir use, efavirenz use, and CD4 nadir, etc.). …”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

“…Groups differed in relation to received drug and hepatitis C virus genotype. All patients received 1,5 mkg per 1 kg body weight per week of Pegaltevir or PegIntron and 800–1400 mg of ribavirin per day. …”
Get full text

Prognostic assessment of early-stage liver cirrhosis induced by HCV using an integrated model of CX3CR1-associated immune infiltration genes by Haozheng Cai, Jing Zhang, Chuwen Chen, Junyi Shen, Xiaoyun Zhang, Wei Peng, Chuan Li, Haopeng Lv, Tianfu Wen

“…However, its role in hepatitis C virus (HCV)-induced early-stage liver cirrhosis remains unexplored. …”
Get full text

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study by Seyed Moayed Alavian, Mohammad Tasavon Gholamhoseini, Heidar Sharafi, Helena HL Borba, Asma Sabermahani, Behzad Hajarizadeh

“…Introduction Low-cost generic direct-acting antiviral (DAA) regimens for treatment of hepatitis C virus (HCV) are available in several low-income/middle-income countries, important for treatment scale-up. …”
Get full text

Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan by Selena M. Sagan, Benoit Dupont, Jason Grebely, Mel Krajden, Sonya A. MacParland, Jennifer F. Raven, Sahar Saeed, Jordan J. Feld, D. Lorne Tyrrell, Joyce A. Wilson

“…Hepatitis C virus (HCV) affects at least 268,000 Canadians and causes greater disease burden than any other infectious disease in the country. …”
Get full text

GB Virus C Infection: Clinical Significance by Xiang Wei Meng, Masafumi Komatsu, Shigetoshi Ohshima, Kunio Nakane, Tomoo Fujii, Takashi Goto, Kazuo Yoneyama, Tomoyuki Kuramitsu, Motokazu Mukaide

“…GB virus C (GBV-C) RNA positivity rates were examined in serum specimens from 231 patients with liver disease (23 patients with hepatitis B, 175 patients with hepatitis C, five patients with hepatitis B virus plus hepatitis C virus coinfection, and 28 patients with non-A, non-B, non-C hepatitis) to clarify the clinical significance of this virus. …”
Get full text

Inflammasome Genes’ Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment by Shady Z. K. Estfanous, Sahar A. Ali, Sameh M. Seif, Sameh H. A. Soror, Dalia H. A. Abdelaziz

“…Chronic inflammation is a pivotal contributor to the liver damage mediated by hepatitis C virus (HCV). The NOD-like receptor, pyrin domain-containing 3 (NLRP3) inflammasome is activated by HCV in both hepatocytes and Kupffer cells. …”
Get full text

Telaprevir: options of application in separate patient groups by M. V. Mayevskaya, I. N. Tikhonov, V. T. Ivashkin

“…Adding of NS3/4A protease inhibitor telaprevir to treatment mode for patients infected with 1-st genotype of hepatitis C virus for 12 wks allowed to increase treatment response rate considerably. …”
Get full text

Seroprevalence of Hepatitis C Viral Infection in Ethiopia: A Systematic Review and Meta-Analysis by Teshiwal Deress, Yihenew Million, Teshome Belachew, Mohabaw Jemal, Mekonnen Girma

“…Background. Hepatitis C virus is a highly genetically heterogenous bloodborne pathogen that is responsible for acute and chronic hepatitis. …”
Get full text

A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma by Yikai Wang, Wenjun Wang, Muqi Wang, Juanjuan Shi, Xiaoli Jia, Shuangsuo Dang

“…Besides, statins have protective effects against hepatocellular carcinoma after hepatitis B virus (odds ratio, 0.44; 95% CI: 0.22–0.85) and hepatitis C virus infections (odds ratio, 0.53; 95% CI: 0.49–0.57). …”
Get full text

Precision oncology through next generation sequencing in hepatocellular carcinoma by Sayali Shinde, Carola Maria Bigogno, Ana Simmons, Nikita Kathuria, Aruni Ghose, Vedika Apte, Patricia Lapitan, Shania Makker, Aydin Caglayan, Stergios Boussios

“…Hepatocellular carcinoma (HCC) is a primary liver cancer that originates from underlying inflammation, often associated with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infections. Despite the availability of treatments, there are high rates of tumour relapse due to the development of drug resistance in infected cells. …”
Get full text